New CLEAR Outcomes data shows bempedoic acid reduces major cardiovascular events across kidney functions.
🔗 https://ow.ly/RMky50YOgJZ
#Cardiology #LipidManagement #CKD #Prevention #CardiovascularRisk
New research shows small, dense LDL-C predicts cardiovascular events like LDL-C in ACS patients on statins. Alirocumab adds benefit.
🔗 Read: https://ow.ly/gJ2z50YNa25
#CardioSky #MedSky #LipidManagement #CardiovascularRisk #ClinicalResearch American Society for Preventive Cardiology
New ACC/AHA Guidelines published today for lipids address measuring Lp(a) and ApoB www.jacc.org/doi/10.1016/...
and gift link summary www.wsj.com/health/welln...
Reboot! 💔 #469 Inpatient Heart Failure Diuresing ‘til the heart’s content
🩺🥼Master inpatient heart failure management! Learn key tips for initiating guideline-directed medical therapy, diuretic therapy pearls, and moe! We are joined by Dr. Gurusher Panjrath
🎧 thecurbsiders.com/curbsiders-p...
A visual representation of the CORALreef Lipids trial, which assessed the efficacy and safety of the oral PCKS9 inhibitor enlicitide decanoate for patients with elevated low-density lipoprotein cholesterol.
Phase 3 CORALreef Lipids trial: PCSK9 inhibitors are an effective alternative to statins for lowering LDL cholesterol, but current formulations are available only in an injectable form. Research findings on an oral PCSK9 inhibitor are summarized in a new Quick Take video. nej.md/4a8fxXz
#MedSky
Original Article | Feb. 5, 2026 A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide (CORALreef Lipids) Fig. 1A. Change in LDL Cholesterol Levels. NEJM identity sits at the bottom.
In the phase 3 CORALreef Lipids trial, the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at 24 weeks and also lowered non-HDL cholesterol, apolipoprotein B, and lipoprotein(a). Adverse events were similar in the two groups. Full trial results: nej.md/4qhQPtQ
#MedSky #CardioSky
How should ApoB and Lp(a) be used as core measures to assess cardiovascular risk?
Join experts Allan Sniderman, George Thanassoulis and Michael Pencina as they unpack the power of these biomarkers – and what they mean for prevention strategies.
Listen now👉 bit.ly/3LjJWcC
#ApoB #LipoproteinA
An inclisiran-based treatment strategy for patients with hypercholesterolemia at high risk for #CVD events helped achieve individual LDL-C goals compared with placebo, based on findings from VICTORION-Difference presented at #ESCCongress. Details: https://bit.ly/463MS43
Treatment with olezarsen significantly reduced triglyceride levels at 6 months compared to placebo in pts w/ moderate hypertriglyceridemia & elevated CV risk, according to results of the Essence-TIMI 73b study presented during #ESCCongress. 🔗 More: https://bit.ly/4g4r50H
For Very High Risk Women - Use of Statins in Pregnancy - cardiovascularbusiness.com/topics/clinical/pharmaceutics/statin-therapy-safe-pregnant-women?utm_source=newsletter&utm_medium=cvb_video @nationallipid.bsky.social @escardio.bsky.social @aspcardio.bsky.social @familyheartfdn.bsky.social
Best publication in Preventive Cardiology I have ever read just out in Nature Reviews Cardiology by Ference, Braunwald, and Catapano. Most statin trials only last 4 years, but now it's clear that being on a statin for decades is key to preventing heart attack & stroke. www.nature.com/articles/s41...
📢NEW NLA & AGS expert clinical consensus on managing #hypercholesterolemia in adults older than 75 years without a history of #ASCVD.
Read the article now: sciencedirect.com/science/arti...
#Cardiosky
ICYMI at #ACC25: #JACCAsia EiC Dr. Jian’an Wang & colleagues presented the results of a phase 2 study demonstrating that SHR-1918, a monoclonal antibody against ANGPTL-3, achieved dose-dependent reductions of LDL
📄: www.jacc.org/doi/10.1016/... #JACC #ASCVD #CardioSky
More data supporting that lower LDL is better. This time in the context of dementia. jnnp.bmj.com/content/earl...
Some Lp(a) (LPA) genetics - Get tested and if abnormal get adult family members tested and get competent advice. If any clinician, including a cardiologist tells you Lp(a) is not important, is experimental or its risk cannot be treated -- run fast out of that office
A fantastic conference with plenty of informative and insightful presentations!
Missed the 2024 ASPC Congress or want to revisit the highlights? 🩺✨ Discover the enduring content from the event and stay ahead in the field!
📚 Access it all here: www.aspconline.org/aspc-2024-en...
#CardioSky #MedSky #ASPC2024 #MedicalEducation #LifelongLearning
Redefining obesity. It is time.
📏BMI is NOT a direct measure of fat
📏BMI does NOT establish the distribution of fat
📏BMI cannot determine with excess fat is a health problem
@thelancet.bsky.social
Lancet Commission
📎 www.thelancet.com/commissions/...
Infographic panel for the Lancet Diabetes & Endocrinology Commission on diagnosing clinical obesity.
🆕 Global Commission proposes overhaul of obesity diagnosis – going beyond BMI to define when obesity is a disease.
Find out more: hubs.li/Q030v_j_0
www.inova.org/our-services...
Please apply with CV, 3LOR and personal statement. We will select our next fellow in January 2025. #CardioOB #Prevention
Ensuring every school is ready for a cardiac emergency is a huge step forward in protecting young hearts. We’re proud to support the #HEARTSact and continue our work with the Smart Heart Sports Coalition.
Great news in this meta-analysis which showed no increase in cardiovascular events in women undergoing fertility treatments.
academic.oup.com/eurheartj/ad...
More evidence that we should he aggressive when treating risk factors like elevated atherogenic lipoproteins in our patients.
Congrats to Dr. Sharma & Inova. What a great honor & opportunity for this Ciccarone Center alumnus.
A bit delayed, but finally, here is a Skytorial (Bluetorial?) on our recent study of guideline recommended statin use in younger adults. #CardioSky #MedSky #CVPrev
www.sciencedirect.com/science/arti...
1/
The times - they are a changing! The evolving definition of obesity by the FDA should revolutionize the way think and treat patients
Shocking to see the @nytimes.com give any credibility to Mark Hyman. His strategy is get rich off off supplements that aren’t evidence based & blood tests that also aren’t evidence based.
It’s one thing to be skeptical of research but this is not that.
#CardioSky
www.nytimes.com/2024/12/18/h...
In this case study of a large medical system, an increased cardiopulmonary disease burden for residents of Maryland that was likely associated with contemporaneous wildfire smoke–based infiltration of polluted or toxic air originating from Western Canada up to 2100 miles remotely was identified
What’s the relation between CAC and osteoporosis? Dr. Matt Budoff now speaking at #WCIRDC25
♥️⤴️ CAC associated with⤵️ bone denisity: osteoporosis =CV risk
♥️ Disease process:osteoclast 🆚 osteoblasts
♥️ Osteopontin may promote atherosclerosis
♥️ therapies for osteoporosis need to be considered
#CardioSky
